CLAIMS

What is claimed is:

1. ~~A method of preventing recurrence of a cancer in a mammal, the method comprising administering to the mammal in need thereof~~Use of a therapeutically effective amount of at least one herbal composition selected from the group consisting of:

(a) an herbal extract YIV-906 comprising herbal extracts of *Scutellaria baicalensis (S), Glycyrrhiza uralensis (G), Paeonia lactiflora (P), and Ziziphus jujuba (Z),* a fraction thereof, or any active chemical present in the herbal extract or the fraction thereof, and

(b) β-glucuronidase treated YIV-906 (YIV-906GU) or a fraction thereof, or any active chemical present in the YIV-906GU or the fraction thereof;

~~wherein the mammal is further administered an effective amount of~~ in the manufacture of a medicament for use in combinatorial therapy for treating and/or preventing recurrence of a cancer in a mammal, wherein the medicament is to be administered to the mammal in combination with an effective amount of at least one immunotherapeutic agent.

2. The ~~method~~ use of claim 1, wherein the cancer comprises a solid tumor.

3. The ~~method~~ use of any one of claims 1-2, wherein the cancer is at least one selected from the group consisting of melanoma, non-small cell lung cancer, renal cell carcinoma, liver cancer, colon cancer, urothelial bladder cancer, and pancreatic cancer.

4. The ~~method~~ use of any one of claims 1-3, wherein the at least one immunotherapeutic agent is an immune checkpoint inhibitor selected from the group consisting of an anti-PD1, an anti-PD-L1, and an anti-CTLA4 inhibitor.

5. The ~~method~~ use of any one of claims 1-4, wherein the at least one immune checkpoint inhibitor is selected from the group consisting of Ipilimumab, Pembrolizumab, Nivolumab, Durvalumab, and Atezolizumab.

6. The ~~method~~ use of any one of claims 1-5, wherein the at least one immunotherapeutic agent is an antibody selected from the group consisting of siglec 15 antibody, anti-phosphatidylserine, anti-OX40, anti-CD73, anti-TIM3, anti-CD24, anti-CD47, anti-PD1, anti-

PDL1, anti-CTLA4, anti-GITR, anti-CD27, anti-CD28, anti-CD122, anti-TIGIT, anti-VISTA, anti-ICOS, and anti-LAG3.

7. The ~~method~~ use of any one of claims 1-6, wherein ~~administering~~ the herbal composition enhances response of the at least one immunotherapeutic agent.

8. The ~~method~~ use of any one of claims 1-7, wherein the ~~herbal composition~~medicament is to be administered to the mammal orally.

9. The ~~method~~ use of any one of claims 1-8, wherein ~~administering~~ the ~~herbal composition~~medicament promotes stimulator of interferon genes (STING) agonist action.

10. The ~~method~~ use of any one of claims 1-9, wherein the ~~herbal composition~~medicament is to be administered to the mammal orally in a form selected from the group consisting of a pill, tablet, capsule, soup, tea, concentrate, dragees, liquids, drops, and gelcaps.

11. The ~~method~~ use of any one of claims 1-10, wherein the therapeutically effective amount of the herbal composition is about 20 mg/day to about 2000 mg/day.

12. The ~~method~~ use of any one of claims 1-11, wherein the therapeutically effective amount of the herbal composition is about 1600 mg/day.

13. The ~~method~~ use of any one of claims 1-12, wherein the ~~herbal composition~~medicament is to be administered twice daily.

14. The ~~method~~ use of any one of claims 1-12, wherein the ~~herbal composition~~medicament is to be administered for about one to about two weeks, followed by a suspension of treatment for at least one week.

15. The ~~method~~ use of any one of claims 1-14, wherein the ~~herbal composition~~medicament is to be administered about 30 mins before ~~administering~~ a chemotherapy or a radiation therapy is to be administered.

16. The ~~method~~ use of claim 15, wherein the medicament is to be administered continuously~~administering in continued~~ for about 4 days.

17. The ~~method~~ use of any one of claims 1-16, wherein the ~~herbal composition~~medicament is to be administered at a time selected from prior to, simultaneously with, and after administration of the one or more immunotherapeutic agent to the mammal.

18. The ~~method~~ use of any one of claims 1-17, wherein the mammal is a human.